CABA (Cabaletta Bio) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)


CABA Cabaletta Bio Inc CABA
34 GF Score
Price $3.03
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio LT-Debt-to-Total-Asset?

Cabaletta Bio CABA +3.75% 34 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cabaletta Bio's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Cabaletta Bio's long-term debt to total assets ratio declined from Mar. 2025 (0.06) to Mar. 2026 (0.02). It may suggest that Cabaletta Bio is progressively becoming less dependent on debt to grow their business.

Cabaletta Bio  (NAS:CABA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cabaletta Bio LT-Debt-to-Total-Asset Related Terms

Cabaletta Bio LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio LT-Debt-to-Total-Asset Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.00 0.03 0.01 0.03 0.02

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.02 0.02 0.02 0.02
CABA
34GF Score
Cabaletta Bio Inc CABA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio LT-Debt-to-Total-Asset Calculation

Cabaletta Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=2.879/165.083
=

Cabaletta Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=3.334/148.146
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Cabaletta Bio (CABA) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cabaletta Bio and its competitors.
Is Cabaletta Bio's LT-Debt-to-Total-Asset too high?
Cabaletta Bio's current LT-Debt-to-Total-Asset is 0.02. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's LT-Debt-to-Total-Asset compare to DNA and CADL?
Cabaletta Bio's LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:Mexico
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score

Get the complete analysis for CABA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.03
Price